Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

The Phase 2 trial, called ANDROMEDA, is the first study to directly compare two types of PSMA-targeted radiopharmaceuticals when used alongside stereotactic body radiotherapy (SBRT), a focused form of ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate cancer. The international study, published in The New England Journal of ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

By Dr Wendy Winnall - PCFA Research Team It's unfortunate that prostate surgery does not always mean the end of prostate ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

September 12, 2012 — The US Food and Drug Administration (FDA) today approved the production and use of a new positron emission tomography (PET) imaging agent, Choline C 11 Injection, which will be ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed ...